Rhythm Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGRhythm Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 21), showing significant lag compared to the market leaders. Earnings contraction of 2% provides fundamental context to the price action. Investors should exercise caution due to high volatility (57% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $86.35 | +11.88% | ABOVE |
| 50 SMA | $87.62 | +10.26% | ABOVE |
| 100 SMA | $96.59 | +0.03% | ABOVE |
| 150 SMA | $99.21 | -2.62% | BELOW |
| 200 SMA | $98.45 | -1.87% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RYTM in an uptrend right now?
RYTM has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is RYTM overbought or oversold?
RYTM's RSI (14) is 62. The stock is in neutral territory, neither overbought nor oversold.
Is RYTM outperforming the market?
RYTM has a Relative Strength (RS) Rating of 21 out of 99. RYTM is currently lagging the broader market.
Where is RYTM in its 52-week range?
RYTM is trading at $96.61, which is 79% of its 52-week high ($122.20) and 62% above its 52-week low ($55.31).
How volatile is RYTM?
RYTM has a Beta of 1.04 and 52-week volatility of 57%. It's more volatile than the S&P 500 - expect bigger swings.